HPV (Human Papillomavirus)

The United States saw a 79% decline in cervical pre-cancer rates between 2008 and 2022 amid vaccine availability and expanded screening. The article says eradication of HPV-related cancers, especially cervical cancer, is feasible. Northern subdistricts had higher hrHPV prevalence than the southern region. Earlier population-based data from Bangladesh estimated hrHPV prevalence at 3.6%. The article presents the HPV vaccine as one of the era's strongest vaccination success stories. More than 500 million HPV vaccine doses had been administered globally by 2022. Gavi met its target of vaccinating 86 million girls in 2025. Women successfully treated for precancerous lesions return to the HPV-free state but remain at risk for future HPV acquisition based on age-specific incidence. Cancer-specific mortality for FIGO stage IV cervical cancer is assumed to occur within the first year of entering that stage. WLHIV demonstrate a lower rate of HPV clearance compared to HIV-negative women, contributing to their elevated cervical cancer risk. HPV causes cervical dysplasia, a precancerous state involving abnormal cells on the cervix. HPV vaccine hesitancy, inequitable access, and aid funding cut…